Compare MTX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTX | HTFL |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2004 | N/A |
| Metric | MTX | HTFL |
|---|---|---|
| Price | $70.56 | $23.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $81.33 | $39.20 |
| AVG Volume (30 Days) | 161.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,072,600,000.00 | N/A |
| Revenue This Year | $5.66 | $40.42 |
| Revenue Next Year | $4.47 | $22.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.54 | $20.13 |
| 52 Week High | $75.30 | $41.22 |
| Indicator | MTX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 40.40 |
| Support Level | $60.02 | $20.13 |
| Resistance Level | $75.30 | $32.52 |
| Average True Range (ATR) | 1.94 | 2.19 |
| MACD | -0.52 | 0.00 |
| Stochastic Oscillator | 27.24 | 30.01 |
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.